Olema Pharmaceuticals, Inc.

NasdaqGS:OLMA Stock Report

Market Cap: US$382.9m

Olema Pharmaceuticals Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

NasdaqGS:OLMA Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
08 Jan 25BuyUS$1,727,370Bain Capital Life Sciences Investors, LLCCompany300,000US$5.76
13 Dec 24BuyUS$4,730,137Logos Global Management, L.P.Company700,761US$6.75
13 Dec 24SellUS$4,730,137Logos Global Management, L.P.Company700,761US$6.75
11 Dec 24SellUS$986,365Sean BohenIndividual109,502US$9.39
11 Dec 24SellUS$316,703Shane William KovacsIndividual35,159US$9.39
11 Dec 24SellUS$250,456Naseem ZojwallaIndividual27,805US$9.39
11 Dec 24SellUS$147,956Cyrus HarmonIndividual16,393US$9.39
11 Dec 24SellUS$234,916David MylesIndividual26,066US$9.39
01 Aug 24SellUS$35,796,000Paradigm Biocapital Advisors LPCompany2,400,000US$14.92
04 Jun 24SellUS$17,448,750Logos Global Management, L.P.Company1,175,000US$14.85

Insider Trading Volume

Insider Buying: OLMA insiders have only sold shares in the past 3 months.

Ownership Breakdown

What is the ownership structure of OLMA?
Owner TypeNumber of SharesOwnership Percentage
General Public2,422,3803.26%
Individual Insiders3,136,2954.23%
VC/PE Firms4,300,0005.79%
Hedge Funds12,651,15917%
Institutions51,693,35469.7%

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 35%.

Top Shareholders

Top 25 shareholders own 79.15% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
9.84%
Paradigm Biocapital Advisors LP
7,304,970US$37.7m32.7%1.4%
7.2%
BVF Partners L.P.
5,346,189US$27.6m-6.47%0.91%
5.79%
Bain Capital Life Sciences Investors, LLC
4,300,000US$22.2m-42.4%2.94%
5.11%
BlackRock, Inc.
3,789,832US$19.6m-1.5%no data
4.98%
Point72 Asset Management, L.P.
3,696,813US$19.1m0.26%0.04%
4.64%
Deep Track Capital, LP
3,442,833US$17.8m-13.9%0.59%
4.32%
Logos Global Management, L.P.
3,208,875US$16.6m0%2.04%
3.93%
MPM BioImpact LLC
2,912,550US$15.0m8.65%1.84%
3.62%
The Vanguard Group, Inc.
2,685,009US$13.9m6.01%no data
2.6%
Lightspeed Ventures, LLC
1,930,894US$10.0m0%0.35%
2.54%
Pictet Asset Management Limited
1,883,354US$9.7m13%0.01%
2.5%
State Street Global Advisors, Inc.
1,857,527US$9.6m-5.71%no data
2.27%
Citadel Advisors LLC
1,683,207US$8.7m34.4%0.01%
2.23%
Avoro Capital Advisors LLC
1,651,982US$8.5m0%0.11%
2.09%
Candriam, Société En Commandite Par Actions
1,551,562US$8.0m2.97%0.02%
2.06%
Wellington Management Group LLP
1,525,484US$7.9m52.1%no data
2.03%
Vivo Capital, LLC
1,505,862US$7.8m0%0.73%
1.83%
Woodline Partners LP
1,357,479US$7.0m0.24%0.04%
1.8%
Dimensional Fund Advisors LP
1,332,792US$6.9m-3.21%no data
1.52%
Balyasny Asset Management L.P.
1,127,589US$5.8m59%0.01%
1.32%
Millennium Management LLC
979,219US$5.1m1,150%no data
1.32%
Morgan Stanley, Investment Banking and Brokerage Investments
977,668US$5.0m347%no data
1.25%
Geode Capital Management, LLC
926,162US$4.8m-0.94%no data
1.19%
Cyrus Harmon
886,168US$4.6m1.47%no data
1.17%
Bank of America Corporation, Asset Management Arm
865,339US$4.5m111%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/20 11:38
End of Day Share Price 2025/02/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Olema Pharmaceuticals, Inc. is covered by 14 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Arlinda LeeCanaccord Genuity
Naureen QuibriaCapital One Securities, Inc.
Zegbeh JallahCapital One Securities, Inc.